 NetScientific PLC LON:NSCI portfolio company, PDS Biotechnology NASDAQ:PDSB said a Phase 2 trial for an immunotherapy treatment for HPV cancer had indicated tumour regression. Presented at the American Society of Clinical Oncology ASCO 2021 Annual Meeting, the data showed results of a phase PDSs candidate PDS0101 in combination with two immune-modulating agents on 25 patients. 